Search results
Results From The WOW.Com Content Network
(Reuters) -Swiss drugmaker Novartis said on Saturday it had received a binding offer from Germany's Siemens Healthineers to acquire its molecular imaging business for Fluorine-18 positron emission ...
FRANKFURT (Reuters) -Novartis has dialled up its sales growth target to 5% per year until 2027, citing demand for innovative drugs after the spin off of its generics business. The medium-term ...
Novartis agreed to acquire U.S. radiopharmaceutical company Mariana Oncology for $1 billion upfront, boosting its portfolio of precision cancer treatments in development, the Swiss drug ...
Reuters first reported on Monday that Switzerland-based Novartis was in advanced talks to acquire MorphoSys, leading to the German biotech firm's shares surging more than 40%. The Swiss group will ...
Valneva along with Dynavax Technologies [11] developed a candidate inactivated whole virus vaccine against COVID-19, VLA2001, [12] derived from its Ixiaro Japanese encephalitis vaccine, which underwent a Phase 1/2 trial in the United Kingdom.
FRANKFURT (Reuters) -Novartis said its experimental drug atrasentan was shown to have a positive effect on an indicator of kidney health in people suffering from a rare type of kidney disease in ...
The Novartis Foundation has been one of the leading organizations in the private sector for international development for the last 35 years. The humanitarian engagement of the Novartis Foundation goes back to the 1960s, when the Basel-based companies Ciba, Geigy, Sandoz, Durand & Huguenin, Hoffmann-La Roche and Lonza founded the Basel Foundation for Developing Countries.
(Reuters) -Drug maker Novartis AG is in advanced talks to acquire MorphoSys AG, a developer of cancer treatments that has a market value of 1.6 billion euros ($1.7 billion), two people familiar ...